AR106496A1 - Células dendríticas activadas de un modo óptimo, que inducen una respuesta inmunitaria antitumoral mayor o mejorada - Google Patents

Células dendríticas activadas de un modo óptimo, que inducen una respuesta inmunitaria antitumoral mayor o mejorada

Info

Publication number
AR106496A1
AR106496A1 ARP160101986A ARP160101986A AR106496A1 AR 106496 A1 AR106496 A1 AR 106496A1 AR P160101986 A ARP160101986 A AR P160101986A AR P160101986 A ARP160101986 A AR P160101986A AR 106496 A1 AR106496 A1 AR 106496A1
Authority
AR
Argentina
Prior art keywords
improved
cells
inducing
immune response
tumor
Prior art date
Application number
ARP160101986A
Other languages
English (en)
Inventor
L Bosch Marnix
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of AR106496A1 publication Critical patent/AR106496A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción provee poblaciones de células que comprenden células dendríticas parcialmente maduras y activadas de un modo óptimo, las cuales se pueden usar para la administración a los individuos que tienen un cáncer y/o un tumor. Las células dendríticas parcialmente maduradas, las que se pusieron en contacto con un agente de maduración de células dendríticas por un lapso variable entre alrededor de 10 y aproximadamente 19 horas, al ser administradas, captan eficientemente y procesan los antígenos tumorales en el área del lugar del tumor, completan la maduración y pueden migrar posteriormente hacia los ganglios linfáticos de un individuo tratado. Una vez que se encuentra en el ganglio linfático, el antígeno presentador de células dendríticas, ahora maduro por completo, segrega las citocinas apropiadas (por ejemplo, TNFa, IL-6, IL-8, y/o IL-12) y se pone en contacto con las células T, induciendo una respuesta clínica y/o inmunitaria antitumoral sustancial y óptima. Composición.
ARP160101986A 2015-06-30 2016-06-30 Células dendríticas activadas de un modo óptimo, que inducen una respuesta inmunitaria antitumoral mayor o mejorada AR106496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562187086P 2015-06-30 2015-06-30

Publications (1)

Publication Number Publication Date
AR106496A1 true AR106496A1 (es) 2018-01-24

Family

ID=57609106

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101986A AR106496A1 (es) 2015-06-30 2016-06-30 Células dendríticas activadas de un modo óptimo, que inducen una respuesta inmunitaria antitumoral mayor o mejorada

Country Status (15)

Country Link
US (2) US11124768B2 (es)
EP (1) EP3317403A4 (es)
JP (2) JP6985939B2 (es)
KR (1) KR20180022949A (es)
CN (2) CN107849537A (es)
AR (1) AR106496A1 (es)
AU (2) AU2016286112B2 (es)
BR (1) BR112017028602A2 (es)
CA (1) CA2990640A1 (es)
HK (1) HK1255084A1 (es)
IL (2) IL256522B1 (es)
MX (2) MX2018000056A (es)
PL (1) PL424035A1 (es)
RU (1) RU2018103235A (es)
WO (1) WO2017004230A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200038440A1 (en) * 2017-02-28 2020-02-06 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
CN117417886B (zh) * 2023-10-20 2024-05-14 广东壹加再生医学研究院有限公司 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
ES2766299T3 (es) * 2001-09-06 2020-06-12 Northwest Biotherapeutics Inc Composiciones y procedimientos para la activación linfocitaria de células dendríticas monocíticas y células T para generar una respuesta Th-1
JP4859169B2 (ja) 2002-12-06 2012-01-25 ノースウエスト バイオセラピューティクス，インコーポレイティド 腫瘍の処置のための、インビトロでの部分的に成熟した樹状細胞の投与
AU2004214896A1 (en) 2003-02-27 2004-09-10 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
KR100887560B1 (ko) 2007-04-24 2009-03-09 크레아젠 주식회사 준성숙 수지상 세포를 포함하는 류마티스 관절염 치료용약제학적 조성물
WO2009062001A1 (en) * 2007-11-08 2009-05-14 Dana-Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
EP2072617A1 (en) 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
MX2010011508A (es) 2008-04-18 2011-05-03 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la nueva presentacion de diabetes autoinmune.
EP2968406A4 (en) * 2013-03-14 2016-10-26 Icahn School Med Mount Sinai AUTOLOGOUS TUMOR LYSAT-FILLED DENDRITIC CELL VACCINE FOR THE TREATMENT OF LIVER CANCER

Also Published As

Publication number Publication date
IL256522A (en) 2018-02-28
IL312668A (en) 2024-07-01
US11124768B2 (en) 2021-09-21
RU2018103235A3 (es) 2019-12-23
MX2018000056A (es) 2018-05-28
JP2018523996A (ja) 2018-08-30
RU2018103235A (ru) 2019-07-31
CN114774356A (zh) 2022-07-22
MX2023001622A (es) 2023-03-09
KR20180022949A (ko) 2018-03-06
CA2990640A1 (en) 2017-01-05
US20220145246A1 (en) 2022-05-12
US20180187145A1 (en) 2018-07-05
EP3317403A4 (en) 2019-07-03
AU2016286112A1 (en) 2018-02-15
JP2022023248A (ja) 2022-02-07
PL424035A1 (pl) 2019-01-02
JP6985939B2 (ja) 2021-12-22
AU2016286112B2 (en) 2023-02-16
IL256522B1 (en) 2024-06-01
AU2023202977A1 (en) 2023-06-01
EP3317403A1 (en) 2018-05-09
HK1255084A1 (zh) 2019-08-02
BR112017028602A2 (pt) 2018-09-04
CN107849537A (zh) 2018-03-27
WO2017004230A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
CL2020002737A1 (es) Métodos para expandir linfocitos infiltrantes de tumores (divisional de la solicitud no. 201902769)
CO2021007362A2 (es) Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
CL2019003390A1 (es) Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer
EA201890960A1 (ru) Натуральные киллеры и клетки ilc3 и их применение
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
AR104296A1 (es) Infusión arterial hepática de células car-t
MXPA05006042A (es) Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
CL2018003284A1 (es) Métodos de tratamiento de enfermedades autoinmunes usando linfocitos t alogénicos.
MX2018007933A (es) Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina.
AR106496A1 (es) Células dendríticas activadas de un modo óptimo, que inducen una respuesta inmunitaria antitumoral mayor o mejorada
CO2020007275A2 (es) Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas
HRP20220419T1 (hr) Terapija matičnim stanicama kod patologija endometrija
CO2018002534A2 (es) Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
PH12019550033A1 (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
AR106926A1 (es) Método para reducir la formación de anticuerpos anti-fármaco (ada) y método de tratamiento de un trastorno proliferativo de celulas b
JOP20200124A1 (ar) طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
CL2015001213A1 (es) Método ex vivo para predecir respuesta a un tratamiento inmunomodulador en pacientes con enfermedad inflamatoria, el cual comprende la cuantificación de las razones entre las concentraciones de citoquinas seleccionadas de ifn-gamma/il-17f, il17f/il-10, il-17f/ifn-gamma e il-10/il17f; y kit para llevar a cabo el método.
AR115203A1 (es) Procesos para generar productos enriquecidos de til para antígenos tumorales específicos de células t
Spain TEBOHO MAKALIMA
RU2015118632A (ru) Тени бактерий L. fermentum 39 для стимулирования врожденного иммунного ответа и их применение
UA117887U (uk) Апарат для ретенції результатів лікування відкритого прикусу

Legal Events

Date Code Title Description
FB Suspension of granting procedure